Relative increases in the antiarrhythmic-induced gA channel appearance frequencies and lifetimes
| gA single-channel properties | Amiodarone | Dronedarone | Propranolol | Pindolol | |||||||
| 3 µM | 10 µM | 0.3 µM | 1 µM | 3 µM | 100 µM | 300 µM | 1,000 µM | 100 µM | 300 µM | 1,000 µM | |
| f13/f13cntrl | 2.5 ± 0.7 | 6.5 ± 0.3 | 2.1 ± 0.1 | 4.2 ± 1.2 | 1.6 ± 0.4 | 4.4 ± 0.3 | 9 | 3 ± 1 | 4.0 ± 1.2 | 5 | |
| f15/f15cntrl | 3.1 ± 0.5 | 3.6 ± 1.2 | 1.7 ± 0.03 | 2.2 ± 0.7 | 1.8 ± 0.6 | 6.5 ± 0.2 | 11 | 2.2 ± 0.4 | 3.4 ± 1.1 | 4 | |
| τ13/τ13cntrl | 1.6 ± 0.2 | 3.5 ± 0.2 | 1.5 ± 0.1 | 2.2 ± 0.2 | 4.6 ± 0.8 | 1.1 ± 0.1 | 1.2 ± 0.03 | 1.8 ± 0.2 | 1.0 ± 0.1 | 1.1 ± 0.1 | 1.4 ± 0.3 |
| τ15/τ15cntrl | 1.5 ± 0.3 | 2.3 ± 0.04 | 1.2 ± 0.1 | 1.6 ± 0.3 | 3.0 ± 0.8 | 1.0 ± 0.05 | 1.1 ± 0.1 | 1.4 ± 0.02 | 1.1 ± 0.1 | 1.2 ± 0.2 | 1.3 ± 0.1 |
| gA single-channel properties | Amiodarone | Dronedarone | Propranolol | Pindolol | |||||||
| 3 µM | 10 µM | 0.3 µM | 1 µM | 3 µM | 100 µM | 300 µM | 1,000 µM | 100 µM | 300 µM | 1,000 µM | |
| f13/f13cntrl | 2.5 ± 0.7 | 6.5 ± 0.3 | 2.1 ± 0.1 | 4.2 ± 1.2 | 1.6 ± 0.4 | 4.4 ± 0.3 | 9 | 3 ± 1 | 4.0 ± 1.2 | 5 | |
| f15/f15cntrl | 3.1 ± 0.5 | 3.6 ± 1.2 | 1.7 ± 0.03 | 2.2 ± 0.7 | 1.8 ± 0.6 | 6.5 ± 0.2 | 11 | 2.2 ± 0.4 | 3.4 ± 1.1 | 4 | |
| τ13/τ13cntrl | 1.6 ± 0.2 | 3.5 ± 0.2 | 1.5 ± 0.1 | 2.2 ± 0.2 | 4.6 ± 0.8 | 1.1 ± 0.1 | 1.2 ± 0.03 | 1.8 ± 0.2 | 1.0 ± 0.1 | 1.1 ± 0.1 | 1.4 ± 0.3 |
| τ15/τ15cntrl | 1.5 ± 0.3 | 2.3 ± 0.04 | 1.2 ± 0.1 | 1.6 ± 0.3 | 3.0 ± 0.8 | 1.0 ± 0.05 | 1.1 ± 0.1 | 1.4 ± 0.02 | 1.1 ± 0.1 | 1.2 ± 0.2 | 1.3 ± 0.1 |
Values represent relative changes in gA channels’ single-channel appearance frequencies (f) and lifetimes (τ), where f or τ in the presence of antiarrhythmics is normalized to that in the absence of antiarrhythmic in the same experiment.